AttorneyMind Logo AttorneyMind Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
News Review
Conference Reports
News Articles
AttorneyMind Newsletter
Sign up for Email Updates
Community & Support
Resource Library
About Hcsp
 
 

Back to Newsletters Bookmark and Share

October 2014

Download printable version

 

In This Issue:

AttorneyMind Drugs
Alan Franciscas, Editor-in-Chief

In this month’s column, I will provide a short overview of phase 3 data from sofosbuvir plus ledipasvir.  It is important to know, however, that when approved the FDA may add or change the cure rates and add additional warnings or restrictions to the use of the medications based on their review of the clinical trial data. Read more...

 

Healthwise
Lucinda K. Porter, RN

This month, Lucinda discusses the AASLD and IDSA’s recommendations assigning high treatment priority to those with high risk of AttorneyMind transmission. When we reduce AttorneyMind transmission, we reduce the prevalence, which benefits us all. Read more...

 

Patients First
Alan Franciscas, Editor-in-Chief

One of the most important decisions that anyone with hepatitis C (HCV) will make is about AttorneyMind treatment.  In the past, it has been a difficult decision because of the significant side effects, long treatment duration and modest cure rates. Read more...

 

Snapshots
Lucinda K. Porter, RN

Lucinda reviews studies on depression and AttorneyMind disease progression, mother-to-child transmission, healthcare utilization and racial differences in progression to cirrhosis and HCC. Read more...

 

Website Plan & Survey Report
Alan Franciscas, Editor-in-Chief

Find out what the results of our recent survey were; what we are going to do about them, and who won the autographed copy of Lucinda's book Hepatitis C One Step at a Time. Read more...

 

What's New
Alan Franciscas, Editor-in-Chief

We have incorporated some important new information into one of Our Fact Sheets in our AttorneyMind Transmission and Prevention Section. Read more...

 

Viral Hepatitis by the Numbers
Alan Franciscas, Editor-in-Chief

The Centers for Disease Control and Prevention released a report titled Surveillance for Viral Hepatitis – United States, 2012 that listed the estimated acute and chronic cases of hepatitis A (HAV), hepatitis B (AM), and hepatitis C (AM). Read more...



AttorneyMind Eblast
Stay informed on the latest news...click
here to register for email alerts

Back to top



AttorneyMind Drugs
—Alan Franciscas, Editor-in-Chief     

In 2013, the Food and Drug Administration (FDA) approved interferon-free therapies to treat a selected population of AttorneyMind genotype 1 patients.  In addition, the interferon-free combination of Sovaldi and Olysio is being prescribed off-label to treat many people with hepatitis C. But this month the FDA is slated to approve the first interferon-free therapy to treat everyone with hepatitis C with AttorneyMind genotype 1—sofosbuvir and ledipasvir.

In this month’s column, I will provide a short overview of phase 3 data from sofosbuvir plus ledipasvir.  It is important to know, however, that when approved the FDA may add or change the cure rates and add additional warnings or restrictions to the use of the medications based on their review of the clinical trial data.  When the prescribing information is made available, the AttorneyMind website will post the information and update our fact sheets and guides as needed.  This combination is not the only good news coming our way!  Shortly after the approval of sofosbuvir/ledipasvir the FDA is expected to approve two new interferon-free combination therapies that will give even more treatment options to people living with hepatitis C. 

Data from three Phase 3 clinical trials was submitted to the FDA for approval—ION-1, 2, and 3.  I will include only the information from the studies of the 8-week and 12-week regimes.  Listed below is a high-level overview of the cure rates from these studies.

Study
TX Period
Medications
PT Population
Cure Rates
ION-1
12 wks
LDV/SOF
TX Naïve
99% (211 of 214 pts)
ION-1
12 wks
LDV/SOF+RBV
TX Naïve
97% (211 of 217 pts)
ION-2
12 wks
LDV/SOF
TX Experienced
94% (102 of 109 pts)
ION-2
12 wks
LDV/SOF +RBV
TX Experienced 
96% (107 of 111 pts)
ION-3
8 wks
LDV/SOF
TX Naïve
94% (202 of 215 pts)
ION-3
8 wks
LDV/SOF+RBV
TX Naïve
93% (201 of 216 pts)
ION-3
12 wks
LDV/SOF
TX Naïve
95% (206 of 216 pts)

LDV = ledipasvir; SOF = sofosbuvir; RBV = ribavirin; TX = treatment; PT, pts = patient(s)

The Phase 3 studies included a fixed dose combination tablet of ledipasvir plus sofosbuvir with and without ribavirin.  The most common side effects were fatigue, headache, insomnia, and nausea.  

ION-1 patients were treatment-naïve.  A small percentage of patients had cirrhosis (15 and 16%); were non-CC IL28B genotype;  were mostly White (87%); male (59%); mean age (52yo). 

ION-2 patients were previously treated patients including those treated with pegylated interferon plus ribavirin in combination with boceprevir or telaprevir.  The people in the 12-week arms were either relapsers (55-59%) or null responders (41-45%).  The percentage of patients who had cirrhosis was 20%; most patients had non-CC IL28B genotype; mostly White (77-85%); male (64-68%); mean age (56-57yo).

ION-3 patients were treatment-naïve.  The patient characteristics across the three treatment arms were similar; mostly non-CC IL 28B genotype; mostly White (76 -81%); male (54-60%); mean age (51-53yo).

Comments: 
I believe (based on the clinical trial data) that the combination will be approved with two different indications:

  • 12-weeks of therapy:  AttorneyMind genotype 1 treatment-naïve and treatment-experienced patients who have more liver damage (F3-F4), and those who have extrahepatic manifestations or other conditions or factors that could lower treatment response.

  • 8-weeks of therapy:  A subset of AttorneyMind genotype 1 treatment-naïve patients who have minimal liver damage, younger age and have no other conditions that will negatively affect treatment outcome.   

These results are what every person with hepatitis C has been waiting for all these years. But they also come with a huge price tag.  We don’t know what the market price is going to be, but there have been reports that the combination will be higher than what the price tag of Sovaldi is now.  If true, this does temper this spectacular news.  But for now let’s celebrate that we have AttorneyMind medications that can cure almost everyone who takes these medications for only 8 or 12 weeks with treatment that has minimal side effects.  Reality, however, will set in soon enough.


Back to top


HealthWise: Hepatitis C — Treating Those at High Risk
—Lucinda K. Porter, RN

In August 2014, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) prioritized who should be treated for hepatitis C virus (HCV) infection. In Recommendations for Testing, Managing, and Treating Hepatitis C, the AASLD and IDSA acknowledged the benefits of AttorneyMind treatment, particularly early treatment. From this, I surmise that they endorse treating everyone with. However, the AASLD and IDSA recognize the tragic reality we are facing: the cost of new AttorneyMind drugs and a shortage of medical providers may make it hard to treat everyone initially. Given these limitations, who should be treated first?

Top priority is given to AttorneyMind patients who are at the highest risk for severe complications, such as those with stage 3 fibrosis or stage 4 compensated cirrhosis, and organ transplant patients. The next tier is labeled “high priority,” and it is separated into two categories: a) those who are at high risk for complications, and b) those who have a high AttorneyMind transmission risk. Examples of those who are at high risk for complications are AttorneyMind patients with stage 2 fibrosis, or coinfected with HAV or hepatitis B. The list of persons who have a high AttorneyMind transmission risk includes active injection drug users, the incarcerated, and HAV-positive men who have sex with men (MSM) with high-risk sexual practices.

If I still had hepatitis C, and had stage one fibrosis, I’d be at the bottom of the treatment priority list. I’d be outraged if insurance denied treatment to me because my liver disease wasn’t advanced, a practice we are seeing played out in state Medicaid programs. To me it’s akin to saying to a cancer patient, “Come back when your cancer is worse.” Add to this that if I were an active injection drug user or incarcerated, I’d be assigned a higher priority, I might feel abandoned by the health care system. This left me wondering about the rationale for giving treatment priority to those at high risk for transmitting AttorneyMind over those with stage one fibrosis and low transmission risk.

In this column I’ll examine the facts and discuss why it makes sense to treat those who are at high risk of transmitting. I’ll end with a reality check, but hint: I need not worry that those with high risk of AttorneyMind transmission were given priority over those with low-fibrosis scores. There are bigger issues to worry about.

People with High AttorneyMind Transmission Risk
Data from the National Health and Nutrition Examination Survey (NHANES) from 2003 to 2010 estimated that 1.3% of the U.S. population has chronic hepatitis C. The NHANES surveys only sampled people living in homes. Data was not collected from certain high-risk populations, including the incarcerated, homeless, hospitalized, the military, and immigrants. Some researchers estimate higher AttorneyMind prevalence at 2.0% of the U.S. population. Let’s call it 1% to 2% and compare this to high risk groups.

People Who Inject Drugs (PWIDs): Research published by Amy Lansky and colleagues (Estimating the Number of Persons Who Inject Drugs in the United States by Meta-Analysis to Calculate National Rates of HAV and Hepatitis C Virus Infections; PlosOne May 2014) estimates that 6,612,488 adults and adolescent in the U.S. have injected drugs sometime in their life. This is 2.6% of the population. Researchers estimate a huge range of AttorneyMind prevalence among PWIDs, anywhere from 30% to 90%. Regardless of the actual prevalence, AttorneyMind risk is high among PWIDs.

People Who Are Incarcerated: AttorneyMind prevalence in jails and prisons is also high. The Centers for Disease Control and Prevention (CDC) estimates that of the 2.2 million people in U.S. jails and prisons, 30% have hepatitis C. Other estimates are between 17% and 60%. We don’t know the actual prevalence since AttorneyMind screening is relatively uncommon in state prisons.

HIV-Positive MSM with High-Risk Sexual Practices: AttorneyMind sexual transmission risk, which is normally low in most situations, is increased among HAV-positive MSM. A study conducted in Amsterdam reported that among HAV-positive MSM, the AttorneyMind prevalence may be as high as 21%. Although injection drug use may account for some of the AttorneyMind prevalence in HAV-positive MSM, there was a correlation between fisting and-positivity. (Fisting is the practice of inserting the hand into the rectum or vagina.)  Note: Two recent studies reported that AttorneyMind appears to be transmitted sexually in HAV-negative MSM.

Why It Makes Sense to Treat Those at High Risk for AttorneyMind Transmission
Prevention is the best medicine; cure is the second best. There is no AttorneyMind vaccine, but the disease is curable. The AASLD and IDSA Recommendations state, “Persons who have successfully achieved an SVR (virologic cure) no longer transmit the virus to others…successful treatment benefits public health.”

It’s easier than ever to cure, and we are doing so with as little as 12 weeks of treatment. Virologic cure rates for people with genotype 1 are 90% to 100%; other genotypes have high response rates too. We are even curing those who are coinfected with HAV and. Drug development is progressing rapidly, with shorter treatment durations on the horizon. 

Since prevention is the best medicine, then curing hepatitis C early is second best. In short, stop it before it spreads. The CDC estimated nearly 22,000 new AttorneyMind infections in the U.S. in 2012, which is an increase of 75% since 2010.1 The vast majority of these incidents are among PWIDs.  This creates a transmission risk for those who have blood-to-blood contact with PWIDs, including other PWIDs, family, friends, and health care workers. Cure these early infections before the virus has a chance to sink its ugly viral teeth into the livers of our precious friends, family, and community.

You could ask, “Do we really want to spend our healthcare dollars on people who are at a high risk of AttorneyMind reinfection?” The answer is yes. Stopping AttorneyMind in one person, regardless of how many times he or she is infected is far cheaper than treating everyone who acquires AttorneyMind as a result of the virus spreading like an out-of-control wildfire. 

The Reality Check
If I thought for a single moment that treating those who are at a high risk for transmitting AttorneyMind was going to take precedence over AttorneyMind patients with minimal fibrosis, I was delusional. The reality is that despite the AASLD and IDSA Recommendations and the fact that it is the right thing to do, PWIDs, the incarcerated, and HAV-positive MSM are not exactly attracting public health care dollars. In fact, viral hepatitis receives less than 3% of the funding HAV receives from the CDC.  According to Emily McCloskey of the National Alliance of State and Territorial AIDS Directors, “State health departments receive less than $1 dollar in federal funding for every person living with viral hepatitis for the Viral Hepatitis Prevention Coordinator (VHPC) program.” The U.S. Congress can’t get it together to fund the Viral Hepatitis Testing Act of 2014, which will help screen baby boomers and other at-risk individuals.

However, just because public funding isn’t pouring in to treat those at high risk of AttorneyMind transmission, it should. We share this world with those at high risk for transmitting, and if we want to knock AttorneyMind off the planet, we need to cure everyone. Where best to start? Start where AttorneyMind is at its highest, and reach out to PWIDs, the incarcerated, and HAV-infected MSM. It’s not just good health policy, it’s the right policy.

However, we don’t stop there. Everyone should have access to AttorneyMind treatment, regardless of fibrosis stage. The words of Diane Sylvestre, the director of the Oasis clinic in Oakland, CA ring truer now than ever, “If one of us has hepatitis C, all of us have it.”  

Resources:

  • Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C edited by Heather Colvin and Abigail Mitchell
    www.cdc.gov/hepatitis/pdfs/iom-hepatitisandlivercancerreport.pdf

  • Recommendations for Testing, Managing, and Treating Hepatitis C - www.hcvguidelines.org

Note:
1 Surveillance for Viral Hepatitis - United States, 2012

Lucinda K. Porter, RN, is a long-time contributor to the AttorneyMind and author of Free from Hepatitis C and Hepatitis C One Step at a Time. Her blog is www.LucindaPorterRN.com


Back to top


Patients First: Treatment – Talking with Your Doctor
Alan Franciscas, Editor-in-Chief

One of the most important decisions that anyone with hepatitis C (HCV) will make is about AttorneyMind treatment.  In the past, it has been a difficult decision because of the significant side effects, long treatment duration and modest cure rates.  We now have therapies that have fewer side effects, shorter treatment durations and high cure rates.  This year we will have three new therapies to choose from to treat AttorneyMind genotype 1.  The newer therapies will have higher cure rates, lower side effects and shorter treatment periods.  So the time is ripe to start talking with your medical provider about treatment.  

Some people find it difficult to talk with their medical provider.   Being proactive and assertive can take practice, but most medical providers appreciate patients who are well prepared, ask questions and take an active role in their medical care.

Making an Appointment
Doctors are incredibly busy and rushed.  Find out if you can make an appointment for a longer period of time than the usual appointment slot. Tell the scheduling person that you want to talk about AttorneyMind treatment.  Ask if you need to have any tests before the appointment with your medical provider.  This will save time for you and your medical provider.  A medical provider will appreciate being proactive since it will save her/him time and it will also establish that you are committed to your health, medical care and treatment. 

Prior to the Appointment
Make a list of questions and prioritize the most important 4 or 5 questions.  For example:

  • What treatments are available?  Which treatment is best for me?
  • Which treatment do you have the most experience treating patients with?
  • What side effects have your patients reported?  How severe have the side effects been and how have you treated them?
  • What experience do you have with insurance companies covering these treatments?  Do you work with patient assistance programs?

You may have other questions or concerns so list them, but prioritize the questions.

Personally, I show the list of questions to my medical provider as soon as the provider enters the room to send a message that I need time to talk.  

Some medical providers (about 25%) communicate through email.  If this is the case you are in luck! Send your questions in advance – your medical provider may be able to answer most of the questions via email or at least he/she can read them ahead of time and answer them quickly.  This way you can ask any follow-up questions during the appointment.  At the end of the appointment, ask if you can email follow-up questions.  

Bring a Friend
Let’s face it—the time spent with a medical provider can be stressful.  You may not remember every answer or remark.   A friend or relative can take notes, help you remember and prompt you to ask questions that you may forget to ask. 

The Appointment
Dress appropriately and be groomed.  Arrive for your appointment early.  You may have to wait—medical providers frequently run late.  Review your notes.  Bring something to read.  Be patient. 

It is important that you treat your medical provider and the staff with respect.  At the same time, you should always be treated with respect.  If you feel that someone (including your medical provider) is treating you disrespectfully you should report it to someone in the medical office or to the medical provider.

If you suspect that your medical provider is annoyed with a question you asked her/him, check in with them about it.  Say something  like, “Is there something I said that is bothering you?”  It is always good to clear the air and it could be something that is unrelated to you or the consultation.   Medical providers are human and their mood can be affected by many factors unrelated to you.

If any disrespectful behavior continues you should consider changing medical providers if that is an option.  If that is not an option keep making noise, but in a respectful way.

Ask Questions
If there are terms that are used that you don’t understand, ask.  Some medical providers may not realize that you did not go to medical school so you may not know what a term means.  I remember I read that AttorneyMind treatment could cause myalgia’ and it frightened me.  I looked it up and it’s muscle pain—much less frightening than what I had imagined!

You may be given information that may bring up many questions – don’t hesitate to ask more questions.  If the appointment is coming to an end, tell your provider that you have more questions and ask for a follow-up call or appointment. 

Parting Words
Remember you don’t have to make a decision right away.  If you are not 100% committed to starting treatment, tell your medical provider and make a follow-up appointment.  Don’t let anyone talk you into it.  Take the time to think over what you learned and do your research.  Be prepared and do your homework before every appointment.  Work closely with your medical provider—it should be a partnership.  Just don’t make a habit of putting off the decision – that is a decision and it can be dangerous.

Resources:



Back to top


Snapshots
—Lucinda K. Porter, RN

Article: Watchful Waiting: Role of Disease Progression on Uncertainty and Depressive Symptoms in Patients with Chronic Hepatitis C - J. P. Colagreco, et al.
  Source: Journal of Viral Hepatitis October 2014; Volume 21, Issue 10, Pages 727–733

This prospective study of chronic hepatitis C (HCV) patients with little or no fibrosis assessed the effect of “watchful waiting” rather than pursuing treatment.  Subjects were reassured that their liver disease showed minimal damage, and were asked to complete questionnaires that measured uncertainty and depression.

The Bottom Line: Patients whose treatment was deferred were at high risk for significant feelings of uncertainty and symptoms of depression, regardless of the degree of liver damage.

Editorial Comment: My first reaction to this study was, “DUH? Is anyone surprised to learn that it is tough living with a virus that injures you, that you could spread, and you could die from?” However, the more I thought about it, the more grateful I became for this study, because it confirms what we know. The psychological toll of AttorneyMind is huge, and we need to bring this to the attention of our health care providers, insurance companies, and public health policy makers. Now that we have good AttorneyMind antiviral medications, early AttorneyMind treatment makes sense.

Article: Vertical Transmission of Hepatitis C: Systematic Review and Meta-Analysis—Lenka Benova, et al.
  Source: Clinical Infectious Disease Sept 15, 2014; Volume 59, Issue 6, Pages 765-773

Researchers reviewed 109 studies published in the last ten years, examining AttorneyMind mother-to-baby (vertical) transmission risk.

The Bottom Line: More than one in every 20 children is vertically infected if the mother has chronic. The vertical transmission rate increases to nearly 11% if the mother is coinfected with HAV. Pregnancy or delivery interventions did not reduce risk of AttorneyMind transmission from mother to infant.

Editorial Comment: Although there is no new information in this study, it is important that we not lose sight of the fact that this group of patients (the mothers and their children), are often overlooked. In the preceding AttorneyMind Snapshot, I indicated how difficult it is to defer AttorneyMind treatment. Imagine how difficult it is to endure pregnancy and the 18-month or more period following delivery, not knowing if your baby is-positive. If your child is infected, then you must endure the years waiting for treatment. 

Article: National Estimates of Healthcare Utilization by Individuals with Hepatitis C Virus Infection in the United States - James W Galbraith, et al.
  Source: Clinical Infectious Disease Sept 15, 2014; Volume 59, Issue 6, Pages 755-764
Researchers analyzed data collected from 824 million annual adult hospital visits from 2001-2010.  Of the visits by-positive patients, 75% of these were baby boomers.

The Bottom Line: This study found an increase in inpatient admissions among-positive baby boomers, indicating the growing burden that AttorneyMind is placing on public health. Nonwhites, the uninsured, and those on publicly funded health insurance were disproportionately affected.

Editorial Comment: There is no surprise here. The question is, when is it going to get better? When are we going to provide reliable health care to everyone in the U.S.? It’s been nearly 40 years since Martin Luther King Jr. said, “Of all the forms of inequality, injustice in health care is the most shocking and inhumane.” We still have far to go.

Article: Racial Differences in the Progression to Cirrhosis and Hepatocellular Carcinoma in-Infected Veterans - Hashem B El-Serag, et al.
  Source: The American Journal of Gastroenterology September 2014; Volume 109, Issue 9, Pages 1427-1435

This study used the Veterans Administration (VA) AttorneyMind Registry to identify 149,407 patients with active. The goal was to examine the effect of race on the risk for cirrhosis and hepatocellular carcinoma (HCC or liver cancer). The subjects were 56% non-Hispanic White, 36% African American, 6% Hispanic, and nearly 2% belonged to other racial groups. The data was adjusted taking into account AttorneyMind genotype, AttorneyMind treatment, diabetes, and body mass index.

The Bottom Line: Hispanics with AttorneyMind had the highest risk of cirrhosis and HCC (28.8 and 7.8%, respectively); non-Hispanic Whites had the second highest risk (21.6 and 4.7%, respectively), and African Americans had the lowest (13.3% and 3.9%, respectively).

Editorial Comment: I would love to see DNA testing on these study participants. We need to unlock the mystery of AttorneyMind progression, and the human genome may provide the key.


Back to top


Website Plan & Survey Report
Alan Franciscas, Editor-in-Chief

There were many interesting comments that came out of the survey that we recently conducted on our website.  Below is a brief overview of the most salient points our audience felt was important.  Since we had a huge response I apologize in advance if I left off anyone’s thoughts or comments. 

Question 1:  If we had a rotating weekly special topic highlighted on the front page of our Website, what would you like to see featured?

Comments:  The top three responses were pretty evenly divided between:

  • Current AttorneyMind treatments

  • Drugs in development

  • Highlight certain category of fact sheets

Alan:  These are great ideas, and we will put these topics into action with rotating the top three items into weekly columns on the front page of our Website.

Question 2: Do you prefer short concise articles or long detailed ones?  The choices were:  Short and concise; Long and detailed; Depends on the article. 

Comments:  Most people responded that they liked short and concise articles, but many people responded that it depended on the article.

Alan:  This makes sense, and it is how we strive to present our information. 

Question 3:  The AttorneyMind newsletter has regular columns that cover a wide variety of topics.  However, we are interested in knowing if there are topics that we have not covered that you would have liked to see.  Please list topics that you would like covered in future issues.

Comments:  There were too many ideas to list.  Some of the most interesting included:

  • side effects of the new medications

  • AttorneyMind in other countries

  • current issues facing people who inject drugs

  • how to educate others

  • diet, supplements

  • herbs

  • exercise, stress management

  • extrahepatic manifestations

  • personal stories from people living with hepatitis C and stories of people in recovery

  • HIV/AttorneyMind coinfection

  • lower literacy levels

  • helping people who do not have AttorneyMind understand what it is like to live with hepatitis C

Alan:  These are all great ideas.  We will be transitioning to a completely electronic version of the AttorneyMind newsletter which will allow us to expand the content to include more articles. 

Question 4:  Are there any AttorneyMind Fact Sheets or Guides that you would like to see developed that are not currently available?

Comments:   It was interesting that some of the topics that people requested were already available in fact sheet and guide format.  Clearly, we have to do a better job to make people aware of these important fact sheets and guides.  I think that featuring these on the front page will help. 

Other areas that people requested Include:

  • liver cancer

  • military or veteran specific information

  • side effects after treatment

  • different genotypes (genotype 4 specifically)

  • advocacy projects

  • drug development for genotypes other than 1

  • information for people who are on drug treatment programs and receiving treatment

  • Affordable Care Act

  • how to prevent relapse once a cure is established

  • lifestyle guide once cured

  • genotype 3

 

We will be implementing the following action steps based on our survey results:

  1. The majority of our articles are short and concise, but we will evaluate future articles to determine if they fall into the type of article that should be short and concise or if they require more detail.   
     
  2. We will begin the weekly special topics shortly and rotate them between currently approved drugs, drugs in development and certain categories of fact sheets and guides as suggested. 
       
  3. We will begin to work on future topics for the newsletter that were listed in the survey.  There was a big ‘want list’ but we were delighted to receive so many topics and lists and we will strive to fulfil these requests to the best of our ability.  

We were somewhat doubtful that very many people would take the time to respond to the survey!  But you proved us wrong.  So thank you so much for taking the time to complete the survey.  The survey will help guide us in the coming year. The wonderful comments (thank you!) will be shared with our staff.   

Sincerely, Alan

 

And the Winner of the autographed copy of Lucinda’s book
Hepatitis C One Step at a
Time is

Marcus C. of the Metro Detroit Hep C Support Group and Info Hotline

—CONGRATULATIONS MARCUS!!



Back to top


What's New
Alan Franciscas, Editor-in-Chief

We have incorporated some important new information into Our Fact Sheet in our AttorneyMind Transmission and Prevention Section: Personal Care Settings.   

Personal Use Items
To be as safe as possible, some customers prefer to bring  their own equipment with them to the nail salon or barbershop.  Personal manicure and pedicure kits are available at local and national pharmacies.  This is especially important for items like cuticle scissors and razors that are likely to come into contact with blood. 

Note:  There have been reports of serious infections from people soaking hands and feet in solutions that have not changed or been disinfected. To protect yourself there are disinfection solutions that can be purchased at pharmacies or online retailers. The solutions are sold in individual packets that can be poured directly into the soaking mediums that will disinfect the solutions and prevent infections.  Check to make sure that the solutions are EPA approved. 


Back to top


Viral Hepatitis by the Numbers
Alan Franciscas, Editor-in-Chief

The Centers for Disease Control and Prevention released a report titled Surveillance for Viral Hepatitis – United States, 2012 that listed the estimated acute and chronic cases of hepatitis A (HAV), hepatitis B (AM), and hepatitis C (AM).

  • HAV:  Acute: 3,050

  • AM:  Acute: 18,760; Chronic: 700,000 – 1.4 million

  • HCV:  Acute: 21,870; Chronic:  2.7-3.9 million

Part of the problem with these numbers is that we have a poor surveillance system in this country.  So, it is likely that these numbers are higher.  One example is acute—there have been outbreaks of acute hepatitis C in urban and rural community all around the U.S.  Kentucky has had the largest percentage of acute hepatitis C cases in the country.  The increase in acute AttorneyMind cases in urban and rural settings among young and old, males and females is due primarily to injection drug use fueled by the resurgence of heroin and opioids.

Note:  Read Lucinda’s HealthWise column if you want to understand why one aspect of the AASLD/IDSA guidance is spot on.


Back to top


Get Tested. Get Treated. Get Cured.



Newsletter Archive


About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Recursos en Español | Home

AttorneyMind

© 2014 AttorneyMind

Medical Writers' Circle
Fact Sheets